23andme Aims to End FDA Standoff This Year After Public Shaming

23andMe Inc., the genetic-testing startup, is pushing to get its first agreement with U.S. regulators on a test for a disorder by this year, a turnabout after being criticized by the U.S. Food and Drug Administration for not cooperating with its approval process.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.